| Literature DB >> 19796623 |
Alexandra Haase1, Ruth Olmer, Kristin Schwanke, Stephanie Wunderlich, Sylvia Merkert, Christian Hess, Robert Zweigerdt, Ina Gruh, Johann Meyer, Stefan Wagner, Lars S Maier, Dong Wook Han, Silke Glage, Konstantin Miller, Philipp Fischer, Hans R Schöler, Ulrich Martin.
Abstract
Induced pluripotent stem cells (iPSCs) may represent an ideal cell source for future regenerative therapies. A critical issue concerning the clinical use of patient-specific iPSCs is the accumulation of mutations in somatic (stem) cells over an organism's lifetime. Acquired somatic mutations are passed onto iPSCs during reprogramming and may be associated with loss of cellular functions and cancer formation. Here we report the generation of human iPSCs from cord blood (CB) as a juvenescent cell source. CBiPSCs show characteristics typical of embryonic stem cells and can be differentiated into derivatives of all three germ layers, including functional cardiomyocytes. For future therapeutic production of autologous and allogeneic iPSC derivatives, CB could be routinely harvested for public and commercial CB banks without any donor risk. CB could readily become available for pediatric patients and, in particular, for newborns with genetic diseases or congenital malformations.Entities:
Mesh:
Year: 2009 PMID: 19796623 DOI: 10.1016/j.stem.2009.08.021
Source DB: PubMed Journal: Cell Stem Cell ISSN: 1875-9777 Impact factor: 24.633